DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/tsg4qh/cellular_therapy) has announced the addition of the "Cellular Therapy in Oncology Drug Pipeline Update 2014" report to their offering.
There are today 82 companies plus partners developing 75 cellular therapy drugs in 164 developmental projects in cancer.
In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 63 drugs.
Cellular Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 32 different targets.
All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 28 out of the 28 studied drug targets so far have been recorded with somatic mutations.
The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 17 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed # 3
- Pre-registration # 1
- Phase III # 8
- Phase II # 30
- Phase I # 26
- Preclinical # 29
- No Data # 1
- Suspended # 6
- Ceased # 63
For more information visit http://www.researchandmarkets.com/research/tsg4qh/cellular_therapy
